Explore the latest in esophageal cancer, including advances in understanding the epidemiology, diagnosis, management, and prevention of the disease.
This cohort study of patients from the 5 Nordic countries examines whether gastroesophageal antireflux surgery is associated with decreased risk of esophageal adenocarcinoma and whether surgically and medically treated patients experience different outcomes.
This study assesses the prevalence of false-negative results and the accuracy of intraoperative consultations on surgical margins in patients undergoing curative intent resection for gastric or gastroesophageal adenocarcinoma.
This randomized clinical trial investigates the effect of an exercise and nutrition conditioning program (prehabilitation) vs usual care on functional capacity in patients undergoing esophagogastric cancer resection.
This case-control study compares disease-free and overall survival among patients with Barrett high-grade dysplasia or esophageal adenocarcinoma with vs without underlying human papillomavirus (HPV) infection demonstrated on biopsy.
This randomized clinical trial examines the effect of the addition of EGFR inhibition to chemoradiation on survival outcomes for patients with esophageal cancer.
This secondary analysis of the TRIO-013 phase 3 randomized clinical trial attempts to determine if gastric acid suppressants such as proton pump inhibitors may impair capecitabine efficacy.
This study assesses the effectiveness of both preoperative chemoradiation with cisplatin and fluorouracil or carboplatin and paclitaxel on recurrence-free survival and overall survival in patients with esophageal cancer.
This study uses disease registry data to examine the association between time intervals from the completion of neoadjuvant chemoradiotherapy to surgical procedure and rates of pathologic complete responses in patients with esophageal cancer.
This study reports that patients with node-positive esophageal adenocarcinoma benefit significantly from neoadjuvant chemoradiation, while patients with node-negative tumors do not gain significant overall survival as compared with surgery alone.
This cohort study reports that the extent of lymphadenectomy during surgery for esophageal cancer is not associated with 5-year all-cause or disease-specific survival.
Using Global Burden of Disease (GBD) 2013 methodology, the GBD Cancer Collaboration investigators estimate mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life years for 28 cancers in 188 countries by sex from 1990 to 2013.
Given the similarities between cervical esophageal cancer treatment groups in all measured rates of survival, Cao et al recommend primary radiotherapy for larynx preservation, with surgery offered subsequently for patients who do not respond to RT.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: